On 17 November, a workshop on “Quantitative Brain Amyloid PET Imaging in Patients with Alzheimer’s Disease” was organised by the US Food and Drug Administration (FDA), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Medical Imaging & Technology Alliance (MITA). The public workshop was held at the FDA White Oak Campus (US) and online. This workshop was intended for a diverse group of scientists, responsible for the evaluation of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain in patients with suspected or confirmed Alzheimer’s disease.
The goals and objectives of the workshop were to:
- Provide a forum for open discussion among stakeholders on the role of Brain Amyloid PET Imaging to address an unmet public health need.
- Seek feedback from industry, academia, and other stakeholders on Brain Amyloid PET Imaging in clinical use and in clinical trials.
- Ensure the leading experts in research academia, pharmaceutical companies, device industries, clinical trials using Brain Amyloid PET Imaging, and patient-advocacy group, have an opportunity to share recent developments among colleagues and public interest groups.
- Facilitate open discussions among all parties in the field of imaging medicine.
- Obtain input from multiple stakeholders on approaches to quantitative imaging in staging of disease, prognosis and monitoring disease progression; implication for diagnostic imaging drug labeling.
We were pleased that Gill Farrar, Andrew Stephens and Juan Domingo Gispert, were invited to talk and present their respective work within AMYPAD.
For more information about the event, please visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-cder-cdrh-snmmi-and-mita-workshop-quantitative-brain-amyloid-pet-imaging-11172022
Please be advised that as soon as a transcript of the public workshop is available, a link to the transcript will be available on the above webpage.
